Best Thymosin Alpha-1 5 mg and 10mg Peptides GMP Factory

Thymosin Alpha-1

Thymosin Alpha-1

Other names:Ta1   thymalfasin

Thymosin Alpha-1 is an immune function regulating peptide containing 28 amino acid residues produced by the thymus. It was first described and characterized in calf thymus by Goldstein et al. in 1977. Several studies have shown that it can enhance cell-mediated immunity in humans and animals.

Production capacity: Provide customization

Large Factory Professional Manufacturers & Factory

Production Carried OUT Under CGMP Regulation and Trackable

ISO9001 & ISO14000

Get a Bulk quotation

If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

Thymosin Alpha-1 Peptide dosage calculator

Referenced Citations

[1]Goldstein AL, Asanuma Y, White A. The thymus as an endocrine gland: properties of thymosin, a new thymus hormone. Recent Prog Horm Res. (1970) 26:505–38. doi: 10.1016/B978-0-12-571126-5.50016-9 

[2]Goldstein AL. The Gordon Wilson lecture. The history of the  development of thymosin: chemistry, biology and clinical applications. Trans Am Clin Climatol Assoc. (1977) 88:79–94.

[3]Asanuma Y, Goldstein AL, White A. Reduction in the incidence of wasting disease in neonatally thymectomized CBA-W mice by the injection of thymosin. Endocrinology. (1970) 86:600–10. doi: 10.1210/endo-86-3-600

[4]Baskies AM, Ommaya AK, Chretien PB. Thymosin alpha1: First clinical trial and comparison with thymosin fraction 5. In: Serrou B, Rosenfeld C, Daniels JC, Saunders JP, editors. Current Concepts in Human Immunology and Cancer Immunomodulation. Amsterdam: Elsevier Biomedical Press (1982). p. 567–74.

[5]Smalley RV, Talmadge J, Oldham RK, Thurman GB. The thymosins–preclinical and clinical studies with fraction V and alpha-I. Cancer Treat Rev. (1984) 11:69–84. doi: 10.1016/0305-7372(84)90017-3

[6]Umeda Y, Sakamoto A, Nakamura J, Ishitsuka H, Yagi Y. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother. (1983) 15:78–83. doi: 10.1007/BF00199694

[7]Ishitsuka H, Umeda Y, Sakamoto A, Yagi Y. Protective activity of thymosin alpha 1 against tumor progression in immunosuppressed mice. Adv Exp Med Biol. (1983) 166:89–100. doi: 10.1007/978-1-4757-1410-4_9

[8]Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother. (1985) 20:189–92. doi: 10.1007/BF00205574

[9]Pica F, Mastino A, Grelli S, Jezzi T, Favalli C. Combined treatment with thymosin alpha 1 and interferon enhances NK activity in immunosuppressed tumor bearing mice. J Chemother. (1989) 1(4 Suppl.):1167–9.

[10]Li W, Song L, Wu S, Xue X, Zhang L, He L, et al. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity. Int J Biol Sci. (2011) 7:618–28. doi: 10.7150/ijbs.7.618

[11]Wang F, Yu T, Zheng H, Lao X. Thymosin alpha1-Fc modulates the immune system and down-regulates the progression of melanoma and breast cancer with a prolonged half-life. Sci Rep. (2018) 8:12351. doi: 10.1038/s41598-018-30956-y

[12]Mutchnick MG, Schaffner JA, Prieto JA, Weller FE, Goldstein AL. Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis. Dig Dis Sci. (1983) 28:328–34. doi: 10.1007/BF01324949

[13] Lau GK, Nanji A, Hou J, Fong DY, Au WS, Yuen ST, et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat. (2002) 9:280–7. doi: 10.1046/j.1365-2893.2002.00361.x

[14] Baek YH, Lee SW, Yoo HS, Yoon HA, Kim JW, Kim YH, et al. Thymosin alpha-1 in combination with pegylated interferon and ribavirin in chronic hepatitis c patients who have failed to prior pegylated interferon and ribavirin treatment. Gut Liver. (2007) 1:87–9. doi: 10.5009/gnl.2007.1.1.87

[15] Baek YH, Lee SW, Yoo HS, Yoon HA, Kim JW, Kim YH, et al. Thymosin alpha-1 in combination with pegylated interferon and ribavirin in chronic hepatitis c patients who have failed to prior pegylated interferon and ribavirin treatment. Gut Liver. (2007) 1:87–9. doi: 10.5009/gnl.2007.1.1.87

[16] Asimina Dominari Thymosin alpha 1: A comprehensive review of the literature World J Virol. 2020 Dec 15; 9(5): 67–78.

Published online 2020 Dec 15. doi: 10.5501/wjv.v9.i5.67

Author of this article:

Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine. 

Scientific Journal paper Author:

Lixin Wang

Corresponding author at: Department of Microbiology and Immunology, Medical School of Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, China. 

Eleftherios Mylonakis

Corresponding author at: Eleftherios Mylonakis 593 Eddy Street, POB, 3rd Floor, Suite 328/330, Providence, RI 02903, USA.

Eran Nizri

Corresponding author at: Department of Surgery A, Tel-Aviv Medical Center, Weizman 6, Tel-Aviv, Israel.

Antonella Minutolo

Department of Experimental Medicine, University of Rome Tor Vergata, Rome 00133, Italy

Pei Luo

Corresponding authors at: State Key Laboratories for Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, PR China (P. Luo); Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave., Wuhan, Hubei 430030, PR China (S. Huang).

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. peptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.

Author of this article:

Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.

Scientific Journal paper Author:

Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK

In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.